Tazemetostat, a New Step in the Development of this Fist-in-class Drug, Tested in a LYSARC Trial
The CALYM Carnot institute and LYSARC are proud to count Epizyme as one of their partners as the U.S. Food and Drug Administration (FDA) has granted Fast Track status to their first-in-class EZH2 inhibitor, tazemetostat, as a potential treatment for relapsed or refractory follicular lymphoma patients with or without EZH2 activating mutations. Fast Track status allows fostering and accelerating the development of important new drugs under study, making them available to patients more quickly.
It is a good news as LYSARC is evaluating the safety and efficacy of tazemetostat in newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) patients treated by chemotherapy (Epi-RCHOP) NCT02889523.
Robert Bazemore, president and chief executive officer of Epizyme, said in a news release. “Our development goal is to bring tazemetostat to patients as quickly as possible, and we look forward to advancing this study throughout 2017.”
Epizyme will present interim effectiveness and safety data from the five cohorts in its ongoing Phase II trial in relapsed or refractory follicular lymphoma and DLBCL at the 14th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, on June 14. The CALYM institute will be more than represented as 10% of the talks will concern its research and particularly results from LYSA and LYSARC.
Take that opportunity to discuss potential mutual interests in the lymphoma field with our teams!
